Home
Search
Search Results
Previously Searched
3214 results found
Expand All
Apply All
3214 results found

BIO Statement on President Trump’s Comments Supporting Biopharmaceutical Competition and Innovation
Press Release  •  January 31, 2017
Washington, DC (January 31, 2017) – BIO issued the following statement regarding President Trump’s comments today supporting biopharmaceutical innovation:
Read More

BIO Submits Comments on FDA proposed rule: Good Laboratory Practice for Nonclinical Laboratory Studies
Letters, Testimony & Comments  •  January 30, 2017
RE: Docket No. FDA-2010-N-0548: The Biotechnology Innovation Organization (BIO) appreciates the opportunity to offer comments to Food and Drug Administration (FDA)’s “Good Laboratory Practice for Nonclinical Laboratory Studies.” 
Read More

BIO Statement on USDA and FDA Actions related to Pre-market Regulatory Oversight of Plant and Animal Organisms
Press Release  •  January 18, 2017
The U.S. Department of Agriculture (USDA) and the U.S. Food and Drug Administration (FDA) published today four documents related to the pre-market regulatory oversight of a variety of biology-based agricultural tools, including genetically engineered plants and plants and animals derived from certain newer precision breeding techniques, such as genome editing.
Read More

BIO’s Jim Greenwood Meets with India’s PM Modi
Press Release  •  January 13, 2017
Delivers Message: India Must Protects Innovators’ Work Product
Read More

BIO Statement on Proposed Maryland Drug Pricing Legislation
Press Release  •  January 10, 2017
BIO's statement  regarding proposed drug pricing legislation within the Maryland Senate.
Read More

BIO submits comments to Merit-Based Incentive Payment System (MIPS) and Alternative Payment Model (APM) Incentive under the Physician Fee Schedule, and Criteria for Physician-Focused Payment Models
Letters, Testimony & Comments  •  December 23, 2016
The Biotechnology Innovation Organization appreciates the opportunity to offer comments to the final rule Medicare Program; Merit-Based Incentive Payment System (MIPS) and Alternative Payment Model (APM) Incentive under the Physician Fee Schedule, and Criteria for Physician-Focused Payment Models.
Read More

BIO Comments on the National Quality Forum Health and Wellbeing 2015-2017 Report
Letters, Testimony & Comments  •  December 23, 2016
BIO appreciates the opportunity to comment on the National Quality Forum (NQF) Health and Wellbeing 2015-2017 report.
Read More

BIO Submits Comments on FDA Draft Guidance: Coordinated Development of Antimicrobial Drugs and Antimicrobial Susceptibility Test Devices
Letters, Testimony & Comments  •  December 23, 2016
Re: Docket No. FDA-2016-N-0001: The Biotechnology Innovation Organization (BIO) is pleased to submit the following comments on the Food and Drug Administration (FDA) Draft Guidance entitled, “Coordinated Development of Antimicrobial Drugs and Antimicrobial Susceptibility Test (AST) devices” 
Read More

BIO CEO & Investor Conference Programming Announced
Business Development, BIO One-on-One Partnering  •  Press Release  •  December 15, 2016
BIO announced programming for the 19th annual BIO CEO & Investor Conference. Held February 13-14 at the Waldorf Astoria in New York, the annual conference provides an environment for investors, analysts, industry executives and others to discover trends in life sciences, network with peers and potential partners and explore investment opportunities. Established and emerging publicly traded and select private biotech companies are the focus of the event.
Read More

BIO Urges the Senate to Pass the 21st Century Cures Act
Letters, Testimony & Comments  •  December 7, 2016
On behalf of the Biotechnology Innovation Organization (BIO), I am writing to offer our strong support H.R. 34, the 21st Century Cures Act, and urge the Senate to pass this important legislation.
Read More